ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
SPRY on Nasdaq
Shares outstanding
98,883,573
Price per share
$10.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
88,975,788
Total reported value
$1,036,369,988
% of total 13F portfolios
0%
Share change
+5,014,425
Value change
+$65,114,283
Number of holders
187
Price from insider filings
$10.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 11% $111,050,917 10,940,977 RA Capital Management, L.P. 29 Sep 2025
Flynn James E 7.8% -12% $134,624,739 -$18,102,531 7,610,217 -12% Deerfield Management Company, L.P. 30 Jul 2025
Rubric Capital Management LP 6.3% $70,556,000 6,200,000 Rubric Capital Management LP 31 Dec 2025
BlackRock, Inc. 5.1% $58,401,450 5,013,000 BlackRock, Inc. 31 Dec 2025

As of 31 Dec 2025, 187 institutional investors reported holding 88,975,788 shares of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY). This represents 90% of the company’s total 98,883,573 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) together control 76% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 11% 10,860,977 0% 1.3% $126,530,382
ORBIMED ADVISORS LLC 8.4% 8,288,510 0% 2.1% $96,561,142
DEERFIELD MANAGEMENT COMPANY, L.P. 7.6% 7,503,812 0% 1.1% $87,419,410
Rubric Capital Management LP 6.3% 6,200,000 +38% 0.86% $72,230,000
BlackRock, Inc. 5.1% 5,085,317 +5.3% 0% $59,243,944
SR One Capital Management, LP 4.1% 4,012,903 0% 6.6% $46,750,320
Aberdeen Group plc 3.6% 3,556,049 +15% 0.06% $41,427,971
VANGUARD GROUP INC 3.5% 3,509,174 +0.25% 0% $40,881,877
STATE STREET CORP 3.3% 3,223,581 +11% 0% $37,554,719
MILLENNIUM MANAGEMENT LLC 3.2% 3,168,406 0.03% $36,911,930
FRANKLIN RESOURCES INC 2.6% 2,543,097 +6.1% 0.01% $29,627,082
UBS Group AG 2.2% 2,210,866 +235% 0.01% $25,756,589
Tyro Capital Management LLC 2% 1,994,852 7.2% $23,240,025
CITADEL ADVISORS LLC 2% 1,954,472 +23% 0.02% $22,769,599
Casdin Capital, LLC 1.6% 1,600,000 0% 1.2% $18,640,000
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,552,870 +3.1% 0% $18,093,898
Southpoint Capital Advisors LP 1.5% 1,500,000 0% 0.41% $17,475,000
Janney Montgomery Scott LLC 1.3% 1,287,832 +6.2% 0.03% $15,003,000
BAMCO INC /NY/ 1.3% 1,268,532 0% 0.04% $14,778,398
GOLDMAN SACHS GROUP INC 0.82% 812,036 -39% 0% $9,460,219
FIL Ltd 0.82% 810,073 0.01% $9,437,350
LEVIN CAPITAL STRATEGIES, L.P. 0.76% 747,506 -2.2% 0.76% $8,708,445
Nextech Invest, Ltd. 0.67% 660,703 0% 0.74% $7,697,190
BANK OF MONTREAL /CAN/ 0.65% 643,407 0% $7,495,692
CenterBook Partners LP 0.57% 568,361 +11% 0.32% $6,621,406

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 88,975,788 $1,036,369,988 +$65,114,283 $11.65 187
2025 Q3 83,632,743 $840,434,931 -$93,311,095 $10.05 187
2025 Q2 84,521,210 $1,475,027,148 +$149,943,852 $17.45 185
2025 Q1 76,226,291 $958,937,759 +$63,838,841 $12.58 182
2024 Q4 71,304,827 $752,320,202 +$68,074,351 $10.55 163
2024 Q3 63,765,651 $925,913,322 +$31,092,478 $14.50 148
2024 Q2 62,590,275 $533,041,807 +$21,909,612 $8.51 112
2024 Q1 59,892,345 $612,088,771 -$16,199,586 $10.22 113
2023 Q4 65,423,068 $358,517,051 -$2,784,476 $5.48 99
2023 Q3 66,524,840 $251,464,826 +$38,754,815 $3.78 94
2023 Q2 55,071,412 $368,976,724 +$11,246,123 $6.70 92
2023 Q1 53,405,274 $347,669,060 +$19,586,591 $6.51 88
2022 Q4 50,164,476 $427,856,540 +$173,112,031 $8.53 72
2022 Q3 30,422,972 $160,377,408 +$24,492,078 $5.28 58
2022 Q2 26,061,019 $110,514,000 -$387,734 $4.24 60
2022 Q1 26,983,988 $94,707,000 -$19,556,342 $3.51 66
2021 Q4 30,103,833 $200,460,000 -$13,223,479 $6.66 71
2021 Q3 28,894,700 $288,363,500 -$42,490,899 $9.98 73
2021 Q2 27,989,545 $864,603,729 +$5,243,899 $30.89 74
2021 Q1 27,691,694 $1,205,836,321 +$139,058,596 $43.63 67
2020 Q4 24,444,347 $1,127,544,026 +$1,117,084,030 $46.34 61